Thank you, Jim Allison

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The year was 1998, location, Italian Alps. Jim and I were attending an intimate Pezcoller meeting organized by David Livingston. At that meeting, Jim presented something I had never seen in the entirety of my career—the eradication of cancer in mice following treatment with an antibody designed to inhibit a T cell checkpoint mechanism.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ronald A. DePinho
Professor, past president, Harry Graves Burkhart III Distinguished University Chair, Department of Cancer Biology, MD Anderson Cancer Center

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
Ronald A. DePinho
Professor, past president, Harry Graves Burkhart III Distinguished University Chair, Department of Cancer Biology, MD Anderson Cancer Center

Login